CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-282-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.29 million
Profitability
Miscellaneous
Employees46
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions
What is CTI BioPharma's stock symbol?
CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."
When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?
Shares of CTI BioPharma reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.
How were CTI BioPharma's earnings last quarter?
CTI BioPharma Corp (NASDAQ:CTIC) announced its quarterly earnings data on Wednesday, March, 13th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.28. The biopharmaceutical company had revenue of $14.11 million for the quarter. CTI BioPharma had a negative return on equity of 47.87% and a negative net margin of 113.11%. View CTI BioPharma's Earnings History.
When is CTI BioPharma's next earnings date?
What price target have analysts set for CTIC?
4 brokers have issued 1 year price targets for CTI BioPharma's shares. Their predictions range from $4.00 to $8.00. On average, they anticipate CTI BioPharma's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 405.1% from the stock's current price. View Analyst Price Targets for CTI BioPharma.
What is the consensus analysts' recommendation for CTI BioPharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.
Has CTI BioPharma been receiving favorable news coverage?
Press coverage about CTIC stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CTI BioPharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
Are investors shorting CTI BioPharma?
CTI BioPharma saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 1,385,151 shares, an increase of 44.2% from the March 15th total of 960,263 shares. Based on an average daily trading volume, of 194,552 shares, the days-to-cover ratio is presently 7.1 days. Approximately 2.6% of the shares of the company are short sold. View CTI BioPharma's Current Options Chain.
Who are some of CTI BioPharma's key competitors?
Some companies that are related to CTI BioPharma include TapImmune (MRKR), Protagonist Therapeutics (PTGX), Syros Pharmaceuticals (SYRS), Concert Pharmaceuticals (CNCE), Aldeyra Therapeutics (ALDX), MEI Pharma (MEIP), Osmotica Pharmaceuticals (OSMT), Galectin Therapeutics (GALT), Aeglea Bio Therapeutics (AGLE), Millendo Therapeutics (MLND), Spero Therapeutics (SPRO), Mersana Therapeutics (MRSN), Ardelyx (ARDX), Zynerba Pharmaceuticals (ZYNE) and Poxel (PXXLF).
What other stocks do shareholders of CTI BioPharma own?
Who are CTI BioPharma's key executives?
CTI BioPharma's management team includes the folowing people:
- Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
- Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
- Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
- Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
- Mr. Ed Bell, Sr. Director of Investor Relations
How do I buy shares of CTI BioPharma?
Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CTI BioPharma's stock price today?
One share of CTIC stock can currently be purchased for approximately $0.99.
How big of a company is CTI BioPharma?
CTI BioPharma has a market capitalization of $57.40 million and generates $26.29 million in revenue each year. The biopharmaceutical company earns $-29,320,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. CTI BioPharma employs 46 workers across the globe.
What is CTI BioPharma's official website?
How can I contact CTI BioPharma?
CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]
MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
